Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $18.74, but opened at $20.79. Nanobiotix shares last traded at $20.09, with a volume of 83,068 shares trading hands.
Analyst Ratings Changes
A number of analysts recently issued reports on NBTX shares. Leerink Partners set a $14.00 price objective on Nanobiotix in a research report on Thursday, September 18th. HC Wainwright reissued a "buy" rating on shares of Nanobiotix in a research report on Friday, September 19th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.00.
Check Out Our Latest Stock Report on Nanobiotix
Nanobiotix Trading Up 9.2%
The company has a fifty day simple moving average of $9.73 and a two-hundred day simple moving average of $6.02.
Hedge Funds Weigh In On Nanobiotix
An institutional investor recently bought a new position in Nanobiotix stock. Millennium Management LLC acquired a new position in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 13,452 shares of the company's stock, valued at approximately $39,000. 38.81% of the stock is currently owned by institutional investors.
Nanobiotix Company Profile
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
